Global Sickle Cell Disease Treatment Market (2019-2023) to Grow at a CAGR of More Than 11% - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Jan 29, 2019--The “Global Sickle Cell Disease Treatment Market 2019-2023” report has been added to ResearchAndMarkets.com’s offering.
The sickle cell disease treatment market will register a CAGR of over 11% by 2023.
Strong pipeline of drugs to drive market growth
The pipeline for sickle cell disease comprises strong pharmaceutical companies with novel therapies in the late stages of clinical trials and various mid and small pharmaceutical companies with early-stage pipeline drugs. The strong efficacy of these drugs in the early stages of clinical trials has led to a positive opinion from the regulatory bodies. Thus, helping the vendors with quick development of these drugs.
High prevalence of sickle cell disease
The global sickle cell disease treatment market has witnessed a significant increase in the number of cases of sickle cell diseases in recent years. For instance, according to the CDC. in 2017, sickle cell diseases affected approximately 100,000 Americans. While it is rather rare in Hispanic-Americans and Asian-Americans, the disease is more common in African-Americans, with the prevalence being as high as one per every 365 people.
Lack of approved therapies
Despite blood transfusion being heavily used to treat sickle cell diseases, the market faces a major challenge from the lack of approved therapies. Currently, the market has only three approved therapies for sickle cell diseases, and six molecules are in Phase Ill of clinical trials.
Key PlayersAddmedica Bristol-Myers Squibb Emmaus Medical Novartis Pfizer
PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: MARKET LANDSCAPE
PART 04: MARKET SIZING
PART 05: FIVE FORCES ANALYSIS
PART 06: MARKET SEGMENTATION BY INDICATIONComparison by indication Sickle cell anemia - Market size and forecast 2018-2023 Sickle beta thalassemia - Market size and forecast 2018-2023 Others - Market size and forecast 2018-2023 Market opportunity by indication
PART 07: CUSTOMER LANDSCAPE
PART 08: GEOGRAPHIC LANDSCAPE
PART 09: DECISION FRAMEWORK
PART 10: DRIVERS AND CHALLENGES
PART 11: MARKET TRENDS
PART 12: VENDOR LANDSCAPE
PART 13: VENDOR ANALYSISVendors covered Vendor classification Market positioning of vendors Addmedica Bristol-Myers Squibb Emmaus Medical Novartis Pfizer
For more information about this report visit https://www.researchandmarkets.com/research/np9xwr/global_sickle?w=4
View source version on businesswire.com:https://www.businesswire.com/news/home/20190129005670/en/
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics:Hematological Drugs
INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL
SOURCE: Research and Markets
Copyright Business Wire 2019.
PUB: 01/29/2019 11:00 AM/DISC: 01/29/2019 11:00 AM